Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.41 |
| ▸ | PGR | P06401 | 10/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292065 | 0.67 | NR3C1 (0.48) | NR3C1PGRNR3C2 | |
| SCHEMBL292885 | 0.66 | NR3C1 (0.38) | NR3C1PGRNR3C2NPC1RAB9A | |
| SCHEMBL292884 | 0.66 | NR3C1 (0.38) | NR3C1PGRNR3C2NPC1RAB9A | |
| Biphenyl SCHEMBL28779130 | 0.63 | NR3C1 (0.64) | NR3C1PGRNR3C2 | |
| SCHEMBL13754609 | 0.63 | NR3C1 (0.66) | NR3C1PGRNR3C2 | |
| SCHEMBL24654847 | 0.63 | L3MBTL1 (0.45) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4469118 | 0.62 | NR3C1 (0.66) | NR3C1PGRNR3C2 | |
| SCHEMBL4468861 | 0.61 | NR3C1 (0.69) | NR3C1PGRNR3C2 | |
| SCHEMBL4474649 | 0.60 | NR3C1 (0.82) | NR3C1PGRNR3C2 | |
| SCHEMBL27778243 | 0.60 | NR3C1 (0.57) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 198/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.